Lupus Foundation Provides Patient Perspective in ICER Drug Assessment

June 2, 2021

The Institute for Clinical and Economic Review (ICER) reviewed two drugs (voclosporin and belimumab) for use in cases of lupus nephritis (LN). The Lupus Foundation of America (LFA) led the way for patients to participate in the review process by building a team of patients, scientists, and doctors. LFA provided input at ICER’s final public meeting as members noted significant value associated with the therapies. Both drugs received ICER’s second highest rating, making them important additions to treating a disease that disproportionately affects marginalized communities.

Toni Grimes remarks, “As a black woman who knows all too well the impact lupus nephritis can have, I wanted to make sure that my voice represented women who look like me and are living with lupus. As a LFA support group facilitator I’m in contact with many lupus warriors throughout Arizona and I hear their concerns about access to care and having safe treatments. By working on the ICER review I was able to be the voice of my community.” Read more here.

(Source: Lupus Foundation of America, 5/11/21)

Share This Story!